Canaccord Genuity Group Cuts Voyager Therapeutics (NASDAQ:VYGR) Price Target to $12.00

Voyager Therapeutics (NASDAQ:VYGR) had its target price cut by Canaccord Genuity Group from $14.00 to $12.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also issued reports on the company. StockNews.com lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Voyager Therapeutics in a research note on Wednesday. Citigroup started coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $14.86.

Voyager Therapeutics Price Performance

NASDAQ:VYGR opened at $3.90 on Thursday. The firm has a market capitalization of $213.04 million, a P/E ratio of 5.49 and a beta of 0.99. Voyager Therapeutics has a one year low of $3.56 and a one year high of $10.66. The company’s 50-day simple moving average is $4.83 and its 200 day simple moving average is $5.82.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24). The company had revenue of $4.39 million during the quarter, compared to the consensus estimate of $16.58 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the firm earned $1.25 earnings per share. On average, equities research analysts expect that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Robin Swartz sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total value of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold 10,778 shares of company stock valued at $58,548 over the last 90 days. Company insiders own 4.53% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in shares of Voyager Therapeutics by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,079,509 shares of the company’s stock worth $6,316,000 after purchasing an additional 6,740 shares in the last quarter. FMR LLC increased its position in Voyager Therapeutics by 26.9% in the third quarter. FMR LLC now owns 92,498 shares of the company’s stock worth $541,000 after buying an additional 19,622 shares in the last quarter. Barclays PLC raised its stake in shares of Voyager Therapeutics by 55.8% in the third quarter. Barclays PLC now owns 104,462 shares of the company’s stock worth $612,000 after buying an additional 37,398 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock valued at $223,000 after buying an additional 7,573 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Voyager Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock valued at $405,000 after buying an additional 2,354 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.